11/10/2022
Intravitreal injection of anti- vascular endothelial growth factor has now become a routine treatment modality for Neo-vascular AMD , diabetic macular edema and vascular occlusion involving macula.
All anti- vascular endothelial growth factor injection are aimed to reduce the intravitreal concentration of vascular endothelial growth factor (VGEF). VEGF is the main culprit molecule with is responsible for retinal edema and abnormal growth of blood vessels in the retina.
Injection of anti-VEGF is a simple 2 minutes procedure. It can be done as a OPD or indoor procedure.
First the eyes are anesthetized with topical drops like proparacaine . Once the eye become numb then the drug is injected in eyes taking all sterile precautions. Usually there are no complications except minor subconjuctival hemorrhage wich usually subside by 2 weeks.
Patients are advised to avoid taking head bath for 10 days after the procedure.
Usually the injections are repeated at interval of 4 - 6 weeks . The number of injection depends on the response,so, regular follow up is what is most important in such cases.
Commonly available anti-VEGF are - bevacezumab , ranibizumab, aflibercept .
Some of new arrivals with promising results are brolucizumab. In case of aflibercept and brolucizumab repeat injections are required after gap of 12 weeks.
Port delivery system PDS are also in phase of development where continuous delivery of drug is tried to maintain adequate level of drug in vitreous for longer duration preferably for more than a year.
Intravitreal drug delivery has become the gold standard for treatment of many retinal diseases, including neovascular age-related macular degeneration (AMD),...